Latest Governance News

SSH Mining Australia has entered a profit share mining agreement with High-Tech Metals to advance the Wagtail Gold Deposit, marking a pivotal step in the Mt Fisher Gold Project's development.

Island Pharmaceuticals has formally requested a Type C meeting with the US FDA to discuss accelerating approval of its antiviral Galidesivir for Marburg virus using the Animal Rule pathway.

Greenvale Energy has initiated its first-ever ground exploration program at the Henbury Uranium Project in the Northern Territory, targeting 21 promising uranium anomalies identified through advanced geophysical analysis.

InFocus Group Holdings launches a new division focused on digital assets, AI, and big data, supported by a conditional $10 million financing from Mythos Group. The move aims to accelerate innovation in gamification and blockchain ventures.

Evolution Energy Minerals Limited’s EV1O securities have been suspended from ASX quotation due to non-compliance with a key listing rule, raising questions about the company’s regulatory standing.

Vection Technologies has expanded its AI contract portfolio by securing an additional $2.1 million through a deepened exclusive partnership with Area12 Consulting, bringing total contracts since May 2025 to $5.7 million.

Sayona Mining has completed its merger with Piedmont Lithium, creating a new lithium entity with equal ownership and a refreshed board. The combined company, soon to be renamed Elevra Lithium, aims to strengthen its position in the global energy transition.

Fat Prophets Global Contrarian Fund Ltd has reported a robust 56% increase in net profit for the year ended 30 June 2025, driven by strong investment returns and a leveraged global equity portfolio. The company also declared a fully franked special dividend, reflecting confidence in its ongoing performance.

PT Aneka Tambang Tbk (ANTAM) reported a remarkable 240% surge in net profit for the half year ended June 30, 2025, driven by robust gold and nickel sales amid a challenging mining sector.

Opthea Limited reported a 26% reduction in net loss for FY2025 despite discontinuing its wet AMD drug after failed Phase III trials. The company settled its Development Funding Agreement with investors, securing liquidity and planning a strategic pivot.

Botanix Pharmaceuticals posted a sharp revenue increase driven by its new hyperhidrosis treatment Sofdra, yet reported a substantial net loss reflecting heavy investment in commercialisation. The company’s strong cash position underpins its path to profitability.

Merino & Co. Limited reported a significant 36% decline in revenues alongside a $2.76 million loss for the fiscal year ended June 2025, marking a stark reversal from the prior year’s modest profit.